Mandate

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised CELLINK AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm Main Market, with an estimated market capitalisation of approximately SEK 4.1 billion. The prospectus was published on 15 April 2020 and the trading on Nasdaq Stockholm commenced on 20 April 2020.

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. CELLINK focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing. The target is to develop and commercialise cell culture technologies, enabling researchers to 3D-print human organs and tissues for pharmaceutical and cosmetic applications.

Vinge’s team has primarily consisted of Anders Strid, Wibeke Sorling, Edin Agic and Johanna Hamrefält (Capital Markets and Public M&A) as well as Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge advises Axcel in connection with the sale of Loopia Group to team.blue

Vinge advises Axcel V in connection with the sale of Loopia Group to team.blue, Europe’s leading digital enabler for entrepreneurs and SMBs and backed by Hg, a leading investor in European and transatlantic software and services businesses.
May 23, 2024

Vinge advises Humana in its acquisition of Team Olivia Norge AS

Humana Group ("Humana") strengthens its offering of high-quality care services in Norway as Human Care Holding AS ("Humana Norway") has entered into an agreement to acquire Team Olivia Norge AS for a purchase price of million SEK 341 on a cash- and debt-free basis.
May 17, 2024

Vinge advises Stendörren in connection with issuance of green capital securities and tender offer

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green subordinated and perpetual capital securities in an amount of SEK 300 million (within a framework of SEK 400 million) and its parallel tender offer in respect of its previously issued capital securities.
May 17, 2024